|
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ErbB4 receptor polymorphism 2368A>C and risk of breast cancer.
|
30336339 |
2018 |
|
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In analysis of selected candidate cancer susceptibility genes, two MSR1 SNPs (rs9325782, GEE p = 0.008 and rs2410373, FBAT p = 0.021) were associated with prostate cancer and three ERBB4 SNPs (rs905883 GEE p = 0.0002, rs7564590 GEE p = 0.003, rs7558615 GEE p = 0.0078) were associated with breast cancer.
|
17903305 |
2007 |
|
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) in 19% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers.
|
28750640 |
2017 |
|
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study.
|
22452962 |
2012 |
|
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A number of single nucleotide polymorphisms (SNPs) in ERBB4 gene have been linked to increase the risk of breast cancer.
|
28508829 |
2018 |
|
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
SNP rs13393577 at chromosome 2q34, located in the Epidermal Growth Factor Receptor 4 (ERBB4) gene, showed a consistent association with breast cancer risk with combined odds ratios (95% CI) of 1.53 (1.37-1.70) (combined P for trend = 8.8 × 10-14).
|
22452962 |
2012 |
|
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to predict potential 3'‑UTR variants of ErbB4 that alter the target binding site of microRNAs (miRNAs) and to clarify the association of the potential variant with the risk of developing breast cancer.
|
27035115 |
2016 |
|
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data present the germ-line ERBB4 variant -815A>T as a novel prognostic marker in high-risk early breast cancer and indicate the presence of rare but potentially oncogenic somatic ERBB4 mutations in breast cancer.
|
25036186 |
2014 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, knockdown of PIAS3 with siRNA partially rescued the inhibitory effect of the ErbB4 ICD on differentiation of MDA-MB-468 breast cancer and HC11 mammary epithelial cells.
|
22584572 |
2012 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overall, the simultaneous quantification of HER3 and HER4 receptor genes by means of FISH might enable the rendering of a more precise stratification of breast cancer patients by providing additional prognostic information.
|
18182100 |
2008 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Administration of heregulin-beta2 (HRG), a ligand for erbB3 and erbB4, to growth arrested T-47D human breast cancer cells leads to activation of both the PI3-kinase and MAP kinase signalling pathways and potent stimulation of cell cycle progression.
|
9652748 |
1998 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results indicate that ERBB4 is a unique coregulator of ER, directly coupling extranuclear and nuclear estrogen actions in breast cancer.
|
16912174 |
2006 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Experimental and clinical data support a growth inhibitory role for HER4 in breast cancer.
|
20603612 |
2010 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
More recently, the other two members of the ErbB receptor family, ErbB3 and ErbB4, have been implicated in antihormone resistance in breast cancer.
|
21396094 |
2011 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Failure to account for isoform-specific functions in previous studies may account for conflicting reports on the role of ERBB4 in breast cancer.
|
25516216 |
2014 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Thus, the roles that ErbB4 plays in human breast cancer are still poorly defined.
|
17120616 |
2006 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
The precise biological role of this oncogenic signaling pathway (which also involves the HER4 gene) in breast cancer is unclear.
|
9563896 |
1998 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
The importance of Her4 expression is, however, still controversially discussed; there are few reports on the clinical significance of HER4, its splice variants, and cleaved HER4 intracellular domains (4ICD) which function differently depending on their localization in breast cancer.
|
25003574 |
2014 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study has implications that miR-141 as well as its target, ERBB4, as a potential target for treating trastuzumab-resistant breast cancers.
|
30746756 |
2019 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
As heterodimerization and signaling partners for human epidermal growth factor receptor 2 (HER2), HER3/HER4 has been implicated in tumorigenic signaling and therapeutic resistance of breast cancer.
|
29127433 |
2018 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy.
|
18454307 |
2008 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent data suggest that HER4 unfavorably affects the endocrine treatment of postmenopausal breast cancer patients with tamoxifen and therefore might represent an additional therapeutic target in luminal breast cancer.
|
31139328 |
2019 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overexpression of heregulin, a potent ligand that activates HER3 and HER4 receptors, plays a significant role in the development of chemotherapy resistance in breast cancer patients.
|
28797930 |
2017 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Conflicting reports of the prognostic value of HER4 in breast cancer may be explained by distinct activities of the HER4 intracellular domain, 4ICD.
|
19808643 |
2009 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Levels of breast cancer 1 (BRCA1), EGF receptor (EGFR, also known as ERBB1), ERBB4, tubulointerstitial nephritis antigen-like 1 (TINAGL1) and ESR1 protein were examined with immunohistochemical analysis using immunofluorescence methods and confocal laser scanning microscopy.
|
28810691 |
2017 |